Vesugen

• Published research contexts, not benefits claimed for this RUO material: KED has been studied in vascular-cell aging, endothelial-marker and atherosclerosis-related models; same-network studies report changes in Ki-67, p53, E-selectin, endothelin-1, connexin expression and SIRT1 in model-specific settings; the 41-participant vascular report and the small polymorbidity report are uncontrolled and cannot establish efficacy; exploratory neuroplasticity findings come from cell and mouse models, and the 5xFAD publication has a formal correction
• No reliable evidence reviewed here supports claims of established anti-aging, neuroprotective, physical-recovery or cardiovascular benefit in humans.

CAS

204271-66-9

Formula

C₁₅H₂₆N₄O₈

Molecular weight

390.39 Da

Appearance

White to off-white lyophilized powder

Purity

≥ 99.0% · target, verify batch COA

Storage

Follow the released-lot COA and supplier instructions. Unless batch documentation specifies otherwise, keep sealed lyophilized KED desiccated, protected from light, and at or below -20°C. The receiving laboratory should validate solvent, concentration, container compatibility and solution hold time, and should minimize repeated freeze-thaw cycles. No universal 7-10-day solution life or 24-month retest period was verified for every lot.

MOQ

On request

Lead time

14–21 days

Vesugen is a trade name associated with the linear tripeptide Lys-Glu-Asp (KED). PubChem CID 87571363 identifies lysyl-glutamyl-aspartic acid with formula C₁₅H₂₆N₄O₈ and molecular weight 390.39 Da. Published work covers cell-culture, organotypic-culture and rodent models, plus two small uncontrolled human reports; it is heavily concentrated in the Khavinson research network and does not constitute an independently replicated therapeutic evidence base. PMID 25051774 describes a 41-participant pre/post study without a reported randomized or placebo-controlled design. PMID 26390612 states 32 participants, although its reported sex counts—18 men and 12 women—sum to 30; this source discrepancy remains unresolved. The 2021 5xFAD mouse paper (PMID 34071923) received a 2025 correction for duplicated imagery in Figures 5 and 8 (PMID 39861198). The correction says the conclusions were unaffected, but the correction must accompany citation of the original paper. This bulk product is an analytical and experimental research material, not a registered medicine or finished dietary supplement.

• Research contexts include identity and impurity-method development; vascular endothelial-cell proliferation and senescence models; endothelin-1, connexin, SIRT1, E-selectin, Ki-67 and p53 assay systems; organotypic and rodent neuroplasticity models; and critical appraisal or replication of the small human observational reports
• These contexts do not establish a clinical indication, recommended route, or therapeutic use.

No validated receptor or human mechanism has been established for KED. Khavinson-network studies report model-specific changes in proliferation, senescence and vascular markers, and some papers use computational peptide-DNA docking to propose promoter-level regulation. These are hypotheses from in vitro, in silico, organotypic or animal systems, not direct structural proof of target binding or a demonstrated human causal pathway. The PubMed abstract for the 2021 5xFAD study attributes specific promoter-sequence matches to EDR, not to KED, so the earlier claim that KED was proven to bind CASP3, MAPT or PSEN1 promoter regions has been removed. No human pharmacokinetic study was identified.

• This bulk peptide is Research Use Only and is not sterile or qualified for human or veterinary administration
• No formal Phase I safety program was identified
• The two small human reports are uncontrolled and do not provide the prospective adverse-event ascertainment needed to establish safety; the second report also contains an unresolved sample-count discrepancy and describes pro-oxidant activity and reduced CD34+ hematopoietic-cell counts alongside its favorable claims
• Pregnancy, lactation, pediatric use, organ impairment, contraindications and drug interactions have not been adequately studied
• The 2021 mouse paper must be cited with its 2025 correction
• Laboratories should follow the SDS, use appropriate PPE, perform a documented risk assessment and obtain the institutional approvals required for the intended model.

Interactions reported in the literature

• No authoritative clinical interaction data or validated combination regimen was identified
• Claims that KED is synergistic or compatible with Epitalon, Pinealon, Cartalax, Cardiogen or other peptides are vendor or community hypotheses, not established safety or efficacy guidance
• In experimental systems, treatments that alter endothelial signaling, proliferation, oxidative stress, gene expression or assay readouts may confound interpretation and should be prespecified as controls where relevant
• This catalog does not provide medication-management or combination advice.

Vesugen10 mg · WHJLP-VES10-260429-E

Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

• Require a released-lot COA that states the exact H-Lys-Glu-Asp-OH identity, molecular formula, theoretical mass, measured intact mass and identity method; chromatographic purity and impurity profile; counterion or salt content; water, residual solvents and net peptide assay
• Use an orthogonal identity method such as LC-MS/MS sequence confirmation in addition to intact mass and HPLC
• For cell or animal research, define endotoxin and bioburden acceptance criteria in the receiving laboratory's protocol
• HPLC area purity alone does not establish peptide content, sequence identity, sterility, clinical grade or equivalence to a marketed product
• Appearance and solution clarity are supportive observations, not substitutes for analytical release testing.

Follow the released-lot COA and supplier instructions. Unless batch documentation specifies otherwise, keep sealed lyophilized KED desiccated, protected from light, and at or below -20°C. The receiving laboratory should validate solvent, concentration, container compatibility and solution hold time, and should minimize repeated freeze-thaw cycles. No universal 7-10-day solution life or 24-month retest period was verified for every lot.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

• 1) PubChem CID 87571363, Lysyl-glutamyl-aspartic acid: C₁₅H₂₆N₄O₈, 390.39 Da and the recorded IUPAC structure; 2) Khavinson V, et al. Neuroprotective Effects of Tripeptides-Epigenetic Regulators in Mouse Model of Alzheimer's Disease. Pharmaceuticals. 2021;14:515. PMID 34071923; PMCID PMC8227791; doi:10.3390/ph14060515; 3) Khavinson V, et al. Correction to the 2021 5xFAD paper. Pharmaceuticals. 2025;18:111. PMID 39861198; PMCID PMC11769113; doi:10.3390/ph18010111; 4) Khavinson VKh, et al. Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging. Adv Gerontol. 2014. PMID 25051766; 5) Kozlov KL, et al. Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis. Adv Gerontol. 2016. PMID 28539025; 6) Khavinson VKh, et al. Molecular aspects of anti-atherosclerotic effects of short peptides. Bull Exp Biol Med. 2014. PMID 25408528; doi:10.1007/s10517-014-2713-8; 7) Study of peptide bioregulators in lower-limb chronic arterial insufficiency and vasculogenic erectile dysfunction. Adv Gerontol. 2014. PMID 25051774; 8) Meshchaninov VN, et al. Synthetic peptides in chronic polymorbidity and organic brain syndrome. Adv Gerontol. 2015. PMID 26390612.

1. 01

   Neuroprotective Effects of Tripeptides-Epigenetic Regulators in Mouse Model of Alzheimer's Disease

   Pharmaceuticals (Basel) · 2021 · peer-reviewed original research (5xFAD mouse and computational models)

   Open source
2. 02

   Correction to Neuroprotective Effects of Tripeptides-Epigenetic Regulators in Mouse Model of Alzheimer's Disease

   Pharmaceuticals (Basel) · 2025 · published correction

   Open source
3. 03

   Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging

   Advances in Gerontology (Uspekhi Gerontologii) · 2014 · peer-reviewed original research (in vitro / molecular docking)

   Open source
4. 04

   Molecular aspects of anti-atherosclerotic effects of short peptides

   Bulletin of Experimental Biology and Medicine · 2014 · peer-reviewed original research (in vitro)

   Open source
5. 05

   Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis

   Advances in Gerontology (Uspekhi Gerontologii) · 2016 · peer-reviewed original research / review

   Open source
6. 06

   Effect of tripeptide Lys-Glu-Asp on physiological activity of neuroimmunoendocrine system cells

   Bulletin of Experimental Biology and Medicine · 2012 · peer-reviewed original research (organotypic culture / animal model)

   Open source
7. 07

   Peptides tissue-specifically stimulate cell differentiation during their aging

   Bulletin of Experimental Biology and Medicine · 2012 · peer-reviewed original research (in vitro, human cell culture)

   Open source
8. 08

   Peptide KED: molecular-genetic aspects of neurogenesis regulation in Alzheimer's disease

   Bulletin of Experimental Biology and Medicine · 2021 · peer-reviewed review article

   Open source